New injection aims to revive immune system in HIV patients
NCT ID NCT07579741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called JL18008 in people with HIV whose immune systems have not fully recovered despite standard antiretroviral therapy. The goal is to see if adding this drug can safely increase CD4+ T cells, which are crucial for fighting infections. The trial involves 30 adults who will receive either the drug or a placebo alongside their regular HIV medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer-led prevention: can gancheros help stop HIV, hepatitis c, and overdose in NYC?
- Small cash rewards may keep HIV-positive mothers in treatment — a trial puts the idea to the test
- Long-acting HIV shot studied in patients with severe kidney problems
- Can two hours of mindfulness ease chronic pain in HIV patients?
- Can a clinic-and-social-media campaign boost HIV prevention among black women?
- Choice of Long-Acting HIV prevention could transform care for young people in rural south africa